Akèy › Hidradénite suppurative
Etid klinik pou Hidradénite suppurative ap rekrite nan Etazini
29 etid pou Hidradénite suppurative ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA9 etid
- Tampa, FL8 etid
- Miami, FL6 etid
- Phoenix, AZ6 etid
- New Orleans, LA5 etid
- Birmingham, AL5 etid
- Dallas, TX5 etid
- New York City, NY5 etid
- Minneapolis, MN4 etid
- Durham, NC4 etid
- The Bronx, NY4 etid
- Cleveland, OH4 etid
- Philadelphia, PA4 etid
- Scottsdale, AZ4 etid
- Santa Clarita, CA4 etid
- Baltimore, MD3 etid
- Los Angeles, CA3 etid
- Sandy Springs, GA3 etid
- Chicago, IL3 etid
- Huntington Beach, CA3 etid
- West Lafayette, IN3 etid
- Bowling Green, KY3 etid
- Boca Raton, FL3 etid
- Norfolk, VA3 etid
- Louisville, KY3 etid
- Evanston, IL3 etid
- Santa Monica, CA3 etid
- Miami Gardens, FL3 etid
- Detroit, MI3 etid
- Houston, TX3 etid
- St. Louis, MO3 etid
- Atlanta, GA3 etid
- Portsmouth, NH3 etid
- Baton Rouge, LA3 etid
- Troy, MI3 etid
- San Francisco, CA3 etid
Pa eta
- Alabama5 etid
- Arizona8 etid
- Florid11 etid
- Georgia8 etid
- Illinois6 etid
- Indiana6 etid
- Kalifòni13 etid
- Kentucky6 etid
- Lwizyàn7 etid
- Maryland3 etid
- Massachusetts10 etid
- Michigan7 etid
- Minnesota4 etid
- Missouri6 etid
- New Hampshire3 etid
- New Jersey3 etid
- New York8 etid
- North Carolina5 etid
- Ohio6 etid
- Pennsylvania7 etid
- South Carolina3 etid
- Texas9 etid
- Utah3 etid
- Virginia3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT07665437ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 18 a 79 · Tout sèks · Mizajou Sep 24, 2026 · NCT07783542Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07828860A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07225569Regulation of Inflammatory Genes in Hidradenitis Suppurativa
Ap rekriteEtid obsèvasyon
Laj 18 a 89 · Tout sèks · Mizajou Sep 21, 2026 · NCT05507125A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Sep 18, 2026 · NCT06888193Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06855498Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Sep 15, 2026 · NCT07049575Targeting Nociceptors in Hidradenitis Suppurativa
Ap rekriteEtid obsèvasyon
Laj 18 a 75 · Tout sèks · Mizajou Sep 10, 2026 · NCT05403710Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06058520Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06326476Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07170917Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 12 a 17 · Tout sèks · Mizajou Aug 6, 2026 · NCT07213973A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 22, 2026 · NCT07384975Myriad™ Augmented Soft Tissue Reconstruction Registry
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05243966The Safety and Efficacy of Roflumilast Foam in HS
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07263230A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou May 29, 2026 · NCT07287644Pelashield™ PainGuard™ vs Restrata® in HS Surgery
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT07316192Radiotherapy for Refractory Hidradenitis Suppurativa
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT07414550Clinical and Biological Characteristics of Hidradenitis Suppurativa
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 13 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT03967600Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
Ap rekriteEtid obsèvasyon
Laj 10 ak plis · Tout sèks · Mizajou Apr 29, 2026 · NCT04115566A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Ap rekriteEtid obsèvasyon
Laj 18 a 71 · Tout sèks · Mizajou Apr 16, 2026 · NCT07123038A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 6, 2026 · NCT07244263The Ohio State University Dermatology Biorepository
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Feb 27, 2026 · NCT03146676A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
Ap rekriteFaz 2
Laj 18 a 90 · Tout sèks · Mizajou Dec 23, 2025 · NCT07077902Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.